ClinicalTrials.gg
CompletedNCT02760368CREDO 1Updated Sep 21, 2023Results posted

Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease

A Phase 3 interventional study of Olokizumab and Placebo in Rheumatoid Arthritis, sponsored by R-Pharm International, LLC. Completed at 40 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-21.

Sponsored by R-Pharm International, LLC (part of R-Pharm) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
428
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing olokizumab in Arthritis, Rheumatoid — none open to participants now, none under way, none of them phase 3. olokizumab · Arthritis, Rheumatoid.

Enrollment
3rd of 10
428 · median 206
Started
2016
with 1 other
Phase 3
4 of 10
none open now
Registered
6th of 10
by date
Lead sponsor
5 of 10
R-Pharm International, LLC

Among the 10 studies testing olokizumab in Arthritis, Rheumatoid, this one is the 3rd largest by enrollment, is one of 2 that started in 2016, is one of 4 in phase 3, and was the 6th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

None of the 10 studies testing olokizumab in Arthritis, Rheumatoid is open now. The open studies under Arthritis, Rheumatoid, anywhere →

About olokizumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing olokizumab in Arthritis, Rheumatoid as a file.
02

Study summary

The purpose of this study was to determine how effective and safe the study drug Olokizumab was in patients with Rheumatoid Arthritis (RA) who had been already receiving, but not fully responding to treatment with methotrexate (MTX).

The primary objective of this study was to evaluate the efficacy of olokizumab (OKZ) 64 mg administered subcutaneously (SC) once every 2 weeks (q2w) or once every 4 weeks (q4w) relative to placebo in subjects with moderately to severely active rheumatoid arthritis (RA) inadequately controlled by methotrexate (MTX) therapy.

Read the detailed description

The goal of this Phase III study was to assess the efficacy, tolerability, and safety of OKZ in subjects with moderately to severely active RA who had responded inadequately to MTX. The primary endpoint of the trial was at Week 12. Olokizumab was expected to reduce the disease activity and improve physical function. The study was expected to provide safety information in a large group of subjects over at least a 24 week period.

The CREDO 1 study included a 4-week Screening Period, a double-blind Treatment Period from Week 0 to Week 24, and a Safety Follow-Up Period from Week 24 to Week 44.

At randomization, a total of 428 eligible subjects were randomly assigned to 1 of 3 treatment groups in a 1:1:1 ratio:

  1. OKZ 64 mg q4w: SC injection of OKZ 64 mg q4w (alternating with SC injection of placebo OKZ q4w to maintain blinding) + MTX.
  2. OKZ 64 mg q2w: SC injection of OKZ 64 mg q2w + MTX.
  3. Placebo: SC injection of placebo q2w + MTX

Throughout the double-blind Treatment Period, all subjects were required to remain on a stable dose of background MTX at 15 to 25 mg/week (or ≥ 10 mg/week if there was documented intolerance to higher doses) with a stable route of administration, and concomitant treatment with folic acid ≥5 mg per week or equivalent is required for all subjects. The last dose of study treatment (OKZ or placebo) was at Week 22 in all groups.

Following Visit 2 (randomization), subjects returned to the study site at least every other week through Week 24 for response and safety assessments as per the study Schedule of Events.

Subjects were classified in terms of their response to study treatment at Week 14, with non-responders defined as subjects in any treatment group who had not improved by at least 20% in both swollen and tender joint counts (66-68 joint assessment). Starting at or as close as possible to Week 14, non-responders were administered sulfasalazine and/or hydroxychloroquine as rescue medication in addition to the assigned treatment.

After completion of the 24-week double-blind Treatment Period, subjects either rolled over into the long-term open-label extension (OLE) study or entered the Safety Follow-Up Period. During the Safety Follow-Up Period, subjects returned for visits +4, +8, and +22 weeks after the last dose of study treatment.

Subjects who discontinued the randomized treatment prematurely were required to come for the End of Treatment (EoT) Visit 2 weeks after the last study treatment administration and then continued with the scheduled study visits as per the Schedule of Events.

The study was conducted at approximately 50 sites across 4 countries globally, which included Russia, Belarus, Turkey, and Bulgaria.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • moderate Rheumatoid Arthritis
  • severe Rheumatoid Arthritis
  • subcutaneous
  • Olokizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects may be enrolled in the study only if they meet all of the following criteria:

  • Subjects willing and able to sign
  • Subjects must have a diagnosis of adult onset RA classified by ACR/EULAR 2010 revised classification criteria for RA for at least 12 weeks prior to Screening.
  • Inadequate response to treatment with MTX for at least 12 weeks prior to Screening at a dose of 15 to 25 mg/week (or ≥10 mg/week if intolerant to higher doses).

    • The dose and means of administering MTX must have been stable for at least 6 weeks prior to Screening.
  • Subjects must be willing to take folic acid or equivalent throughout the study
  • Subjects must have moderately to severely active RA disease as defined by all of the following:

    • ≥6 tender joints (68 joint count) at Screening and baseline; and
    • ≥6 swollen joints (66 joint count) at Screening and baseline; and
    • CRP above at Screening based on the central laboratory results.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of any other inflammatory arthritis or systemic rheumatic disease (e.g., gout, psoriatic or reactive arthritis, Crohn's disease, Lyme disease, juvenile idiopathic arthritis, or systemic lupus erythematosus). However, subjects could have secondary Sjogren's syndrome or hypothyroidism
  • Subjects who were Steinbrocker class IV functional capacity (incapacitated, largely or wholly bed-ridden or confined to a wheelchair, with little or no self-care)
  • Prior exposure to any licensed or compound directly or indirectly targeting IL-6 or IL-6R (including tofacitinib or other Janus kinases and spleen tyrosine kinase [SYK] inhibitors)
  • Prior treatment with cell-depleting therapies, including anti-CD20 or investigational agents (e.g., CAMPATH, anti-CD4, anti-CD5, anti-CD3, and anti-CD19)
  • Prior use of bDMARDs, with the following exception:

    • Subjects who discontinued TNFi therapy due to a reason other than lack of efficacy were allowed to enter the study (TNFi therapy was not to be discontinued to facilitate a subject's participation in the study but should instead have been previously discontinued as part of a subject's medical management of RA). The use of TNFi therapy within the following windows prior to baseline was exclusionary:
    1. 4 weeks for etanercept
    2. 8 weeks for infliximab
    3. 10 weeks for adalimumab, certolizumab, and golimumab
  • Use of parenteral and/or intra-articular within 4 weeks prior to baseline
  • Use of oral glucocorticoids greater than 10 mg/day prednisone (or equivalent), or change in dosage within 2 weeks prior to baseline
  • Prior documented history of no response to hydroxychloroquine and sulfasalazine
  • Prior use of cDMARDs (other than MTX) within the following windows prior to baseline (cDMARDs were not to be discontinued to facilitate a subject's participation in the study, but should instead have been previously discontinued as part of a subject's medical management of RA):

    1. 4 weeks for sulfasalazine, azathioprine, cyclosporine, hydroxychloroquine, chloroquine, gold, penicillamine, minocycline, or doxycycline
    2. 12 weeks for leflunomide unless the subject has completed the following elimination procedure at least 4 weeks prior to baseline: Cholestyramine at a dosage of 8 grams 3 times daily for at least 24 hours, or activated charcoal at a dosage of 50 grams 4 times daily for at least 24 hours
    3. 24 weeks for cyclophosphamide
  • Vaccination with in the 6 weeks prior to baseline or planned vaccination with live vaccines during the study
  • Participation in any other investigational drug study within 30 days or 5 times the terminal half-life of the investigational drug, whichever is longer, prior to baseline
  • Other treatments for RA (e.g., Prosorba Device/Column) within 6 months prior to baseline
  • Use of intra-articular hyaluronic acid injections within 4 weeks prior to baseline
  • Use of non-steroidal anti-inflammatory drugs (NSAIDs) on unstable dose or switching of NSAIDs within 2 weeks prior to baseline
  • Previous participation in this study (randomized) or another study of OKZ
  • Subjects with acute or chronic viral or C infection as detected by blood tests at Screening (e.g., positive for hepatitis B surface antigen [HBsAg], total hepatitis B core antibody [anti-HBc], or virus antibody [HCV Ab])

    a. Subjects who were positive for hepatitis B surface antibody (anti-HBs), but negative for HBsAg and anti-HBc, were eligible

  • Subjects with infection
  • Subjects with:

    1. Suspected or confirmed current active TB disease or a history of active TB disease
    2. Close contact (i.e., sharing the same household or other enclosed environment, such as a social gathering place, workplace, or facility, for extended periods during the day) with an individual with active TB within 1.5 years prior to Screening.
  • Concurrent or a history of malignancy within the last 5 years (with the exception of successfully treated carcinoma in situ of the cervix and successfully treated basal cell carcinoma and squamous cell carcinoma not less than 1 year prior to Screening [and no more than 3 excised skin cancers within the last 5 years prior to Screening])
  • Subjects with any infection requiring oral antibiotic or antiviral therapy in the 2 weeks prior to Screening or at baseline, injectable anti-infective therapy in the last 4 weeks prior to baseline, or serious or recurrent infection with a history of hospitalization in the 6 months prior to baseline
  • Subjects with evidence of disseminated herpes zoster infection, zoster encephalitis, meningitis, or other non-self-limited herpes zoster infections in the 6 months prior to baseline
  • Subjects with planned surgery during the study or surgery ≤4 weeks prior to Screening and from which the subject had not fully recovered, as judged by the Investigator
  • Subjects with diverticulitis or other symptomatic GI conditions that might predispose the subject to perforations, including subjects with a history of such predisposing conditions (e.g., diverticulitis, GI perforation, or ulcerative colitis)
  • Pre-existing central nervous system demyelinating disorders (e.g., multiple sclerosis and optic neuritis)
  • History of chronic alcohol or drug abuse as judged by the Investigator
  • Female subjects who are pregnant, currently lactating, have lactated within the last 12 weeks, or who were planning to become pregnant during the study or within 6 months of last dose of study treatment
  • Female subjects of (unless permanent cessation of menstrual periods, determined retrospectively after a woman had experienced 12 months of natural amenorrhea as defined by the amenorrhea with underlying status [e.g., correlative age] or 6 months of natural amenorrhea with documented serum follicle-stimulating hormone levels >40 mIU/mL and estradiol \<20 pg/mL) who were not willing to use a highly effective method of during the study and for at least 6 months after the last administration of study treatment OR Male subjects with partners of childbearing potential not willing to use a highly effective method of contraception during the study and for at least 3 months after the last administration of study treatment;
  • Subjects with a known to any component of the OKZ drug product, or placebo
  • Subjects with a known hypersensitivity or to any component of the rescue medication
  • History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
428 participants (actual)

Study arms

  • Experimental
    Arm 1: Olokizumab q4w

    Olokizumab 64 mg Subcutaneous q4w +placebo+ Methotrexate (oral) in order to maintain the blind, subjects randomized to receive OKZ q4w will receive placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)

    Drug: Olokizumab · Drug: Placebo

  • Experimental
    Arm 2: Olokizumab q2w

    Olokizumab 64 mg Subcutaneous q2w + Methotrexate (oral)

    Drug: Olokizumab

  • Placebo comparator
    Arm 3: Placebo

    Placebo Subcutaneous q2w + Methotrexate (oral)

    Drug: Placebo

Interventions

  • 160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial

  • DrugPlacebo

    sodium chloride 0.9% solution supplied in polypropylene plastic ampoules of 10 mL cartons to contain 10 ampoules

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects Achieving American College of Rheumatology 20% (ACR20) Response

    A responder was defined as any subject satisfying ACR20 criteria and remaining on randomized treatment and in the study at Week 12. The calculations were based on a ≥ 20% improvement from baseline in the swollen joint count (SJC) assessed in 66 joints and in the tender joint count (TJC) assessed in 68 joints; and a ≥ 20% improvement from baseline in at least 3 of the 5 remaining core set measures: Patient Global Assessment of Disease Activity (Visual Analog Scale (VAS) assessment), Patient Assessment of Pain (VAS assessment), Health Assessment Questionnaire-Disability Index (HAQ-DI), Physician Global Assessment (VAS assessment), Level of acute phase reactant (CRP or ESR, using level of CRP in this study).

    Time frame: at Week 12

Secondary outcomes

  1. Percentage of Subjects Achieving Low Disease Activity

    Defined as Disease Activity Score 28 (DAS28) (CRP) \< 3.2, and remaining on randomized treatment and in the study at Week 12.

    Time frame: at Week 12

  2. Improvement of Physical Ability From Baseline to Week 12, as Measured by the Health Assessment Questionnaire Disability Index (HAQ-DI)

    Change of physical ability from baseline (the last available assessment prior to the first dose of the study treatment) to week 12, as measured by HAQ-DI. The HAQ-DI total score ranges from 0 (the best outcome) to 3 (the worst outcome).The HAQ-DI assesses the degree of difficulty experienced in 8 domains (dressing and grooming, arising, eating, walking, hygiene, reach, grip, common daily activities) of daily living activities using 20 questions. Each domain consists of 2 or 3 items. For each question the level of difficulty is scored from 0 (without any difficulty, the best outcome) to 3 (unable to do, the worst outcome). Each category is given a score by taking the maximum score of each question. The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered. If fewer than 6 categories had responses, no disability score was calculated.

    Time frame: Baseline to Week 12

  3. Percentage of Subjects Achieving American College of Rheumatology 50% (ACR50) Response

    A responder was defined as any subject satisfying ACR50 criteria and remaining on randomized treatment and in the study at Week 24. The calculations were based on a ≥ 50% improvement from baseline in the swollen joint count (SJC) assessed in 66 joints and in the tender joint count (TJC) assessed in 68 joints; and a ≥ 50% improvement from baseline in at least 3 of the 5 remaining core set measures: Patient Global Assessment of Disease Activity (Visual Analog Scale (VAS) assessment), Patient Assessment of Pain (VAS assessment), Health Assessment Questionnaire-Disability Index (HAQ-DI), Physician Global Assessment (VAS assessment), Level of acute phase reactant (CRP or ESR, using level of CRP in this study).

    Time frame: at Week 24

  4. Percentage of Subjects With Clinical Disease Activity Index (CDAI) ≤ 2.8 (Remission)

    Percentage of subjects with Clinical Disease Activity Index (CDAI) ≤ 2.8 (remission) and remaining on randomized treatment and in the study at Week 24

    Time frame: at Week 24

07

Results

Posted Oct 30, 2020

Participant flow

Enrollment was conducted at 42 clinical sites (in Belarus, Bulgaria, Russia,Turkey) between May 2016 and April 2018. 785 patients were included, 357 patients screen-failed, 428 patients were randomized (143 patients in OKZ q2w +MTX group, 142 patients in OKZ q4w +MTX group, 143 patients in Placebo q2w +MTX group). 1 subject was randomized by mistake and didn't receive the study treatment. The primary efficacy analysis set included 428 subjects, and the safety analysis set included 427 subjects.

Participant flow — Overall Study
MilestoneArm 1: Olokizumab q4w + MethotrexateArm 2: Olokizumab q2w + MethotrexateArm 3: Placebo + Methotrexate
Started142143143
Completed134130132
Not completed81311
Withdrew: Withdrawal by subject8129
Withdrew: Screen failure001
Withdrew: Death010
Withdrew: Withdrawal by sponsor001

Outcome measures

PrimaryPercentage of Subjects Achieving American College of Rheumatology 20% (ACR20) Response

A responder was defined as any subject satisfying ACR20 criteria and remaining on randomized treatment and in the study at Week 12. The calculations were based on a ≥ 20% improvement from baseline in the swollen joint count (SJC) assessed in 66 joints and in the tender joint count (TJC) assessed in 68 joints; and a ≥ 20% improvement from baseline in at least 3 of the 5 remaining core set measures: Patient Global Assessment of Disease Activity (Visual Analog Scale (VAS) assessment), Patient Assessment of Pain (VAS assessment), Health Assessment Questionnaire-Disability Index (HAQ-DI), Physician Global Assessment (VAS assessment), Level of acute phase reactant (CRP or ESR, using level of CRP in this study).

Time frame:
at Week 12
Reported as:
Count of participants · Participants
Percentage of Subjects Achieving American College of Rheumatology 20% (ACR20) Response
ParticipantsArm 1: Olokizumab q4w + MethotrexateArm 2: Olokizumab q2w + MethotrexateArm 3: Placebo q2w + Methotrexate
Percentage of Subjects Achieving American College of Rheumatology 20% (ACR20) Response1009137
Statistical analysis
  • Arm 2: Olokizumab q2w + Methotrexate vs Arm 3: Placebo q2w + Methotrexate · Chi-squared · p = <0.0001 · Risk difference (rd): 0.378 · 97.5% CI 0.248 to 0.4892x2 chi-square test
  • Arm 1: Olokizumab q4w + Methotrexate vs Arm 3: Placebo q2w + Methotrexate · Chi-squared · p = <0.0001 · Risk difference (rd): 0.445 · 97.5% CI 0.318 to 0.5522x2 chi-square test
SecondaryPercentage of Subjects Achieving Low Disease Activity

Defined as Disease Activity Score 28 (DAS28) (CRP) \< 3.2, and remaining on randomized treatment and in the study at Week 12.

Time frame:
at Week 12
Reported as:
Count of participants · Participants
Percentage of Subjects Achieving Low Disease Activity
ParticipantsArm 1: Olokizumab q4w + MethotrexateArm 2: Olokizumab q2w + MethotrexateArm 3: Placebo q2w + Methotrexate
Percentage of Subjects Achieving Low Disease Activity55475
Statistical analysis
  • Arm 2: Olokizumab q2w + Methotrexate vs Arm 3: Placebo q2w + Methotrexate · Chi-squared · p = <0.0001 · Risk difference (rd): 0.294 · 97.5% CI 0.197 to 0.3892x2 chi-square test
  • Arm 1: Olokizumab q4w + Methotrexate vs Arm 3: Placebo q2w + Methotrexate · Chi-squared · p = <0.0001 · Risk difference (rd): 0.352 · 97.5% CI 0.251 to 0.4492x2 chi-square test
SecondaryImprovement of Physical Ability From Baseline to Week 12, as Measured by the Health Assessment Questionnaire Disability Index (HAQ-DI)

Change of physical ability from baseline (the last available assessment prior to the first dose of the study treatment) to week 12, as measured by HAQ-DI. The HAQ-DI total score ranges from 0 (the best outcome) to 3 (the worst outcome).The HAQ-DI assesses the degree of difficulty experienced in 8 domains (dressing and grooming, arising, eating, walking, hygiene, reach, grip, common daily activities) of daily living activities using 20 questions. Each domain consists of 2 or 3 items. For each question the level of difficulty is scored from 0 (without any difficulty, the best outcome) to 3 (unable to do, the worst outcome). Each category is given a score by taking the maximum score of each question. The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered. If fewer than 6 categories had responses, no disability score was calculated.

Time frame:
Baseline to Week 12
Reported as:
Mean · score on a scale
Improvement of Physical Ability From Baseline to Week 12, as Measured by the Health Assessment Questionnaire Disability Index (HAQ-DI)
score on a scaleArm 1: Olokizumab q4w + MethotrexateArm 2: Olokizumab q2w + MethotrexateArm 3: Placebo q2w + Methotrexate
Improvement of Physical Ability From Baseline to Week 12, as Measured by the Health Assessment Questionnaire Disability Index (HAQ-DI)-0.52 ± 0.046-0.55 ± 0.047-0.23 ± 0.044
Statistical analysis
  • Arm 2: Olokizumab q2w + Methotrexate vs Arm 3: Placebo q2w + Methotrexate · ANCOVA · p = <0.0001 · Least squares mean difference: -0.34 · 97.5% CI -0.47 to -0.21
  • Arm 1: Olokizumab q4w + Methotrexate vs Arm 3: Placebo q2w + Methotrexate · ANCOVA · p = <0.0001 · Least squares mean difference: -0.36 · 97.5% CI -0.49 to -0.23
SecondaryPercentage of Subjects Achieving American College of Rheumatology 50% (ACR50) Response

A responder was defined as any subject satisfying ACR50 criteria and remaining on randomized treatment and in the study at Week 24. The calculations were based on a ≥ 50% improvement from baseline in the swollen joint count (SJC) assessed in 66 joints and in the tender joint count (TJC) assessed in 68 joints; and a ≥ 50% improvement from baseline in at least 3 of the 5 remaining core set measures: Patient Global Assessment of Disease Activity (Visual Analog Scale (VAS) assessment), Patient Assessment of Pain (VAS assessment), Health Assessment Questionnaire-Disability Index (HAQ-DI), Physician Global Assessment (VAS assessment), Level of acute phase reactant (CRP or ESR, using level of CRP in this study).

Time frame:
at Week 24
Reported as:
Count of participants · Participants
Percentage of Subjects Achieving American College of Rheumatology 50% (ACR50) Response
ParticipantsArm 1: Olokizumab q4w + MethotrexateArm 2: Olokizumab q2w + MethotrexateArm 3: Placebo q2w + Methotrexate
Percentage of Subjects Achieving American College of Rheumatology 50% (ACR50) Response696111
Statistical analysis
  • Arm 2: Olokizumab q2w + Methotrexate vs Arm 3: Placebo q2w + Methotrexate · Chi-squared · p = <0.0001 · Risk difference (rd): 0.350 · 97.5% CI 0.239 to 0.4502x2 chi-square test
  • Arm 1: Olokizumab q4w + Methotrexate vs Arm 3: Placebo q2w + Methotrexate · Chi-squared · p = <0.0001 · Risk difference (rd): 0.409 · 97.5% CI 0.296 to 0.5092x2 chi-square test
SecondaryPercentage of Subjects With Clinical Disease Activity Index (CDAI) ≤ 2.8 (Remission)

Percentage of subjects with Clinical Disease Activity Index (CDAI) ≤ 2.8 (remission) and remaining on randomized treatment and in the study at Week 24

Time frame:
at Week 24
Reported as:
Count of participants · Participants
Percentage of Subjects With Clinical Disease Activity Index (CDAI) ≤ 2.8 (Remission)
ParticipantsArm 1: Olokizumab q4w + MethotrexateArm 2: Olokizumab q2w + MethotrexateArm 3: Placebo q2w + Methotrexate
Percentage of Subjects With Clinical Disease Activity Index (CDAI) ≤ 2.8 (Remission)11120
Statistical analysis
  • Arm 2: Olokizumab q2w + Methotrexate vs Arm 3: Placebo q2w + Methotrexate · Chi-squared · p = <0.0002 (2x2 chi-square test) · Risk difference (rd): 0.084 · 97.5% CI 0.032 to 0.151
  • Arm 1: Olokizumab q4w + Methotrexate vs Arm 3: Placebo q2w + Methotrexate · Chi-squared · p = <0.0003 (2x2 chi-square test) · Risk difference (rd): 0.077 · 97.5% CI 0.027 to 0.143

Adverse events

Collected over All Adverse Events (AE) were collected from the signature of the informed consent form until the last visit of the subject in the study (up to 22 weeks after the final dose of study treatment) regardless of relationship to study treatment. Any SAE with a start date after the Safety Follow-Up Period was not required to be reported unless the Investigator thought that the event might be related to either the study treatment, study treatment administration, or a protocol procedure.. Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 1: Olokizumab q4w + Methotrexate0/142 (0%)8/142 (5.6%)53/142 (37.3%)
Arm 2: Olokizumab q2w + Methotrexate1/143 (0.7%)8/143 (5.6%)51/143 (35.7%)
Arm 3: Placebo q2w + Methotrexate0/142 (0%)4/142 (2.8%)35/142 (24.6%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventArm 1: Olokizumab q4w + MethotrexateArm 2: Olokizumab q2w + MethotrexateArm 3: Placebo q2w + Methotrexate
Alanine aminotransferase increasedInvestigations4/1422/1431/142
Aspartate aminotransferase increasedInvestigations3/1420/1430/142
Subcutaneous abscessInfections and infestations0/1422/1430/142
Rheumatoid arthritisMusculoskeletal and connective tissue disorders0/1422/1431/142
GastroenteritisInfections and infestations0/1420/1431/142
PneumoniaInfections and infestations0/1420/1431/142
FistulaMusculoskeletal and connective tissue disorders1/1420/1430/142
Obstructive pancreatitisGastrointestinal disorders1/1420/1430/142
Drug-induced liver injuryHepatobiliary disorders1/1420/1430/142
Cervix carcinoma stage IINeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1420/1430/142
Most frequent other events
Showing 10 of 11
Most frequent other events
EventArm 1: Olokizumab q4w + MethotrexateArm 2: Olokizumab q2w + MethotrexateArm 3: Placebo q2w + Methotrexate
Alanine aminotransferase increasedInvestigations30/14225/14311/142
Aspartate aminotransferase increasedInvestigations19/14216/14310/142
NeutropeniaBlood and lymphatic system disorders9/1425/1432/142
LeukopeniaBlood and lymphatic system disorders7/1428/1434/142
Neutrophil count decreasedInvestigations7/1426/1433/142
White blood cell count decreasedInvestigations6/1427/1434/142
NasopharyngitisInfections and infestations3/1424/1436/142
Upper respiratory tract infectionInfections and infestations6/1422/1434/142
AnaemiaBlood and lymphatic system disorders3/1424/1436/142
Gamma-glutamyltransferase increasedInvestigations6/1423/1434/142

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Arm 1: Olokizumab q4w + MethotrexateArm 2: Olokizumab q2w + MethotrexateArm 3: Placebo q2w + MethotrexateTotal
<=18 years0000
Between 18 and 65 years129125124378
>=65 years13181950
Age, Continuous
Age, Continuous(years)Arm 1: Olokizumab q4w + MethotrexateArm 2: Olokizumab q2w + MethotrexateArm 3: Placebo q2w + MethotrexateTotal
Mean49.1 ± 12.0752.0 ± 11.7752.7 ± 11.2951.3 ± 11.79
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1: Olokizumab q4w + MethotrexateArm 2: Olokizumab q2w + MethotrexateArm 3: Placebo q2w + MethotrexateTotal
Female118116120354
Male24272374
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Arm 1: Olokizumab q4w + MethotrexateArm 2: Olokizumab q2w + MethotrexateArm 3: Placebo q2w + MethotrexateTotal
participants — Asian0011
participants — Black or African American0000
participants — White142143142427
participants — Other/Mixed0000
Region of Enrollment
Region of Enrollment(participants)Arm 1: Olokizumab q4w + MethotrexateArm 2: Olokizumab q2w + MethotrexateArm 3: Placebo q2w + MethotrexateTotal
Bulgaria612927
Russia129124128381
Belarus77620
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Arm 1: Olokizumab q4w + MethotrexateArm 2: Olokizumab q2w + MethotrexateArm 3: Placebo q2w + MethotrexateTotal
Mean26.40 (14.88 to 46.23)26.62 (16.98 to 45.52)26.93 (17.46 to 51.56)26.65 (14.88 to 51.56)
Baseline Disease Severity
Baseline Disease Severity(Participants)Arm 1: Olokizumab q4w + MethotrexateArm 2: Olokizumab q2w + MethotrexateArm 3: Placebo q2w + MethotrexateTotal
Inactive (DAS28 (CRP) ≤ 3.2)0000
Moderately Active (DAS28 (CRP) > 3.2 to ≤ 5.1)21182261
Very Active (DAS28 (CRP) > 5.1)121123119363
08

Study locations

40 sites
  • City Clinical Hospital #1
    Minsk, 220013, Belarus
  • Vitebsk Regional Clinical Hospital
    Vitebsk, 210037, Belarus
  • DCC 'Sv. Pantaleymon' OOD
    Pleven, 5800, Bulgaria
  • UMHAT "Kaspela", EOOD
    Plovdiv, 4002, Bulgaria
  • UMHAT "Sv. Ivan Rilski", EAD
    Sofia, 1431, Bulgaria
  • MC "Synexus - Sofia", EOOD
    Sofia, 1784, Bulgaria
  • Regional State Budgetary Healthcare Institution "Barnaul City Hospital #4"
    Barnaul, Altai Region 656050, Russian Federation
  • Medical Center LLC "Maksimum Zdoroviya"
    Kemerovo, Kemerovo Oblast 650066, Russian Federation
  • SAHI of Kemerovo region "Regional Clinical Hospital for War Veterans"
    Kemerovo, Kemerovskaya Oblast 650000, Russian Federation
  • Budgetary Healthcare Institution "Kursk Regional Clinical Hospital" of Healthcare Committee of Kursk region
    Kursk, Kurskaya Oblast 305007, Russian Federation
  • SPb SBHI "Clinical Rheumatological Hospital #25", Fourth Rheumatology Unit
    Saint Petersburg, Leningradskaya Oblast 190068, Russian Federation
  • FSBEI HE "First Moscow State Medical University n.a. I.M. Sechenov of MoH of Russian Federation", UCH #1
    Moscow, Moscovskaya Oblast 119435, Russian Federation
  • FSBEI HE "FMSMU n.a. I.M. Sechenov of MoH of RF", University Hospital #2, Departament of New Drugs Introduction
    Moscow, Moscovskaya Oblast 119435, Russian Federation
  • SBEI HPE "First Moscow State Medical University n.a. I.M. Sechenov of MoH of Russian Federation" UCH #3
    Moscow, Moscovskaya Oblast 119435, Russian Federation
  • State Budgetary Healthcare Institution of Moscow "City Clinical Hospital #1 n.a. Pirogov" Healthcare Departament of Moscow
    Moscow, Moscovskaya Oblast 19049, Russian Federation
  • State Budgetary Healthcare Institution "City Clinical Hospital # 15 n.a O.M. Filatov" of Moscow Healtheare Department
    Moscow, Moscow Region 111539, Russian Federation
  • SBHI of Moscow "City Clinical Hospital #4 of Moscow Healthcare Departament"
    Moscow, Moskovskaya Oblast 115093, Russian Federation
  • SBHI of Nizhny Novgorod Region "Nizhny Novgorod Regional Clinical Hospital n.a.Semashko"
    Nizhniy Novgorod, Nizhegorodskaya Oblast 603126, Russian Federation
  • State Autonomous Healthcare Institution of Novosibirsk region "City Polyclinic #1"
    Novosibirsk, Novosibirsk Oblast 630099, Russian Federation
  • LLC "Clinical Diagnostic Center "Ultramed"
    Omsk, Omskaya Oblast 644024, Russian Federation
  • Budgetary Healthcare Institution of Omsk Region "Regional Clinical Hospital"
    Omsk, Omskaya Oblast 644111, Russian Federation
  • SBHI of the Republic of Karelia "Republican Hospital named after V.A. Baranov"
    Petrozavodsk, Republic Of Karelia 185019, Russian Federation
  • State Budgetary Healthcare Institution "Republican Clinical Hospital n.a. G.G. Kuvatov"
    Ufa, Respublic Of Bashkortostan 450005, Russian Federation
  • SBEI HPE "Rostov State Medical University" of Ministry of Health of the Russian Federation
    Rostov, Rostovskaya Oblast 344022, Russian Federation
  • State Healthcare Institution "Regional Clinical Hospital"
    Saratov, Saratovskaya Oblast 410053, Russian Federation
  • SBEI HPE "SSMU n.a. V.I. Razumovsky of MoH of RF", Clinical Hospital n.a. S.R. Mirotvorcev, Therapeutic Departament
    Saratov, Saratovskaya Oblast 410054, Russian Federation
  • Non-governmental Healtheare Institution "Regional Clinical Hospital at Smolensk station of OJSC "Russian Railways"
    Smolensk, Smolenskaya Oblast 214025, Russian Federation
  • SBHI of Stavropol Region "Stavropol Regional Clinical Hospital"
    Stavropol', Stavropol Region 355030, Russian Federation
  • State Budgetary Healthcare Institution of Sverdlovsk Region "Sverdlovsk Regional Clinical Hospital #1"
    Ekaterinburg, Sverdlovskaya Oblast 620102, Russian Federation
  • SBEI HPE "Ural State Medical University" of MoH of RF based MBI "Central City Clinical Hospital #6"
    Ekaterinburg, Sverdlovskaya Oblast 620149, Russian Federation
  • State Autonomous Healthcare Institution "Republican Clinical Hospital of Ministry of Health of Tatarstan Republic
    Kazan', The Republic Of Tatarstan 420064, Russian Federation
  • State Healthcare Institution of Tula region "Tula Regional Clinical Hospital"
    Tula, Tulskaya Oblast 300053, Russian Federation
  • State Healthcare Institution "Ulyanovsk Regional Clinical Hospital"
    Ulyanovsk, Ulyanovskaya Oblast 432063, Russian Federation
  • SBHI of Vladimir Region "Regional Clinical Hospital", Rheumatology Departament
    Vladimir, Vladimirskaya Oblast 600023, Russian Federation
  • State Autonomous Helthcare Institution of Yaroslavl region "Clinical Hospital of Emergency Care n.a. Solovyev"
    Yaroslavl', Yaroslavsakaya Oblast 150003, Russian Federation
  • SBHI "Yaroslavl Regional Clinical Hospital", Rheumatology department
    Yaroslavl', Yaroslavskaya Oblast 150062, Russian Federation
  • FSBSI "Scientific Research Institute of Rheumatology n.a. V.A. Nasonova"
    Moscow, 115522, Russian Federation
  • City Clinical Hospital №5 of Nizhny Novgorod
    Nizhny Novgorod, 603005, Russian Federation
  • Ryazan State Medical University n.a. I.P. Pavlov based on Regional Clinical Cardiology Dispensary
    Ryazan, 390026, Russian Federation
  • SBHI "North-West Federat Medical Research Center n.a. V.A.Almazov" of the Ministry of Healthcare of the Russian Federation
    Saint Petersburg, 197341, Russian Federation
09

References and documents

Publications

  • Nasonov E, Fatenejad S, Feist E, Ivanova M, Korneva E, Krechikova DG, Maslyanskiy AL, Samsonov M, Stoilov R, Zonova EV, Genovese M. Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study. Ann Rheum Dis. 2022 Apr;81(4):469-479. doi: 10.1136/annrheumdis-2021-219876. Epub 2021 Aug 3. PubMed 34344706 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2016 to primary completion in Aug 2018, 27 months.

Results were first posted in Oct 2020, 2 years 2 months after primary completion.

Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 27 months is above that.

Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2016
First posted
May 3, 2016
StartActual
May 19, 2016
Primary completionActual
Aug 2018
CompletionActual
Oct 2018
Results first posted
Oct 30, 2020
Last update
Sep 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02760368
Collaborators
Quintiles, Inc., OCT Clinical Trials, Mene Research
Responsible party
Sponsor
First posted
May 3, 2016
Start date
May 19, 2016
Primary completion
Aug 2018
Completion
Oct 2018
Results posted
Oct 30, 2020
Last update
Sep 21, 2023

Study contacts

Mikhail Samsonov
study director · R-Pharm

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olokizumab

Start the discussion